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The concept of cancer stem cells (CSCs) is based on a
hierarchic model of cancer whereby cells within a tumour
exhibit distinct biological characteristics and only CSCs
are able to grow indefinitely and to maintain the neoplas-
tic process. The molecular and cellular characteristics of
CSCs are thought to be due to genetic and epigenetic
states reminiscent of those normal stem cells. Precisely,
cancer arise from the neoplastic transformation of stem
cells or committed-progenitor cells [1] through two types
of events. First, normal stem cells can acquire genetic
alterations that alter its growth control, increase its resis-
tance to apoptosis and interfere with cell differentiation.
Second, non-stem cells can be altered by the oncogenic
process to reacquire the self-renewal properties of nor-
mal stem cells. In both cases, these characteristics confer
a particular resistance to drugs, implying that CSCs are
involved in the persistence of tumour cells during treat-
ment and consequently, are responsible of relapses.
The concept of CSCs has come from pioneering studies
on acute myeloid leukemia (AML) which have defined a
distinct subpopulation of tumour cells, the leukemia initi-
ating cells (LICs), characterized by their capacity to initiate
the disease when transplanted into imuno-deficient mice
[2,3]. A confounding issue in the field has been the equa-
tion of CSCs with the cell of origin of acute leukemias.
Indeed, these original studies and subsequent work sug-
gested that AML derived from the malignant transforma-
tion of hematopoietic stem cells (HSCs) [4,5]. However,
growing evidence based on cellular and molecular studies
led to the recognition that the cell of origin of AML is a
committed progenitor that normally lack any potential for
self-renewal [6,7]. This controversy may be reconciled by
assuming that AMLs may represent in some cases a stem
cell disorder, while in other cases, the reacquisition of
stem cell characteristics by a committed progenitor [8].
The situation is different in paediatric acute lymphoblas-
tic leukemia (ALL), where there is evidence that leukemia
initiating activity is observed not only in the immature cell
population but also in populations corresponding to a
range of normal precursor cells [9,10]. Precisely, the analy-
sis of leukemic and pre-leukemic stem cell populations in
a pair of identical twins indicate that the putative stem cell
responsible for initiating and maintaining B-ALL are not a
fixed cell identity but evolve both in genotype and pheno-
type [11]. Comforting this observation, a process of clonal
evolution at the level of LIC populations was provided
both in B-ALL and T-ALL. Indeed, the molecular investi-
gation of individual LIC helped to establish a complex
clonal architecture of individual leukemia, showing that
LIC are genetically heterogeneous due to the process of
clonal evolution [12-14].
T-acute lymphoblastic leukemia (T-ALL) represents
about 15% of paediatric leukemias. Several studies in these
last years have, in part, elucidated the molecular mechan-
ism of T-ALL transformation. Indeed, T-leukemogenesis
is a multi-step process characterized by the acquisition of
several oncogenic events. Especially, genes encoding the
SCL transcription factor and its nuclear partners LMO1
and LMO2 are frequently deregulated in T-ALL. Further-
more, activating mutations of NOTCH1 are found in more
than 50% of T-ALL cases, and are frequently associated
with chromosomal abnormalities in the SCL and/or
LMO1/2 locus [15,16], implying that these mutational
events frequently collaborate during neoplastic transfor-
mation of thymocytes. It was originally proposed that the
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phenotype of the tumor reflects the cell of origin of T-ALL
[17]. However, recent studies indicate that fully trans-
formed T-leukemic cells are functionally heterogeneous
and may originate from the leukemic transformation of an
early T-cell progenitor [18,19]. Furthermore, it has been
recently shown that the overexpression of the LMO2
oncogene in the thymus induce the emergence of a pre-
leukemic stem cell (pre-LSC) population [20] but the iden-
tification of the cell of origin of T-ALL and the mechan-
isms by which these oncogenes reprogram normal
thymocytes to become T-LIC remain unclear. We took
advantage of a transgenic mouse model that closely repro-
duces paediatric T-ALL to define oncogenic events during
the pre-leukemic phase.
We show that SCL-LMO1 inhibit thymocyte differentia-
tion at the double negative to double positive transition,
via inhibition of two transcription factors that are essential
in the thymus, HEB and E2A [21,22]. Moreover, SCL-
LMO1 reprograms thymocyte progenitors to confer
abnormal self-renewal capacity. The acquisition of stem
cell-like properties establishes a pre-leukemic state in thy-
mocytes by causing an expansion of the CD4-CD8- double
negative (DN) population of progenitors that actively pro-
liferate under the influence of the pre-TCR and are there-
fore at risk of acquiring mutations. Strikingly, our data
indicate that the pre-TCR favors the acquisition of Notch1
mutations in SCL-LMO1 pre-leukemic stem cells [23].
Finally, SCL, LMO1 and NOTCH1 together induce a poly-
clonal disease in transgenic mice, which is comparable to
that induced by transplantation of a single leukemic stem
cell. We therefore conclude that these three oncogenes are
sufficient to transform DN thymocytes.
In summary, we show that in T-ALL, the target cell of
transformation by the SCL-LMO1 oncogenes are double
negative thymocytes that acquire aberrant self-renewal
activities but remain non-leukemogenic. Acquisition of
activating Notch1 mutations then transforms these thymo-
cyte progenitors into leukemic stem cells [23].
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